Is elimination of HCV in 2030 realistic in Central Europe

Robert Flisiak; Dorota Zarębska-Michaluk; Sona Frankova; Ivica Grgurevic; Bela Hunyady; Peter Jarcuska; Limas Kupčinskas; Michael Makara; Marieta Simonova; Jan Sperl; Ieva Tolmane; Adriana Vince

doi:10.1111/liv.14834

Is elimination of HCV in 2030 realistic in Central Europe

Robert Flisiak
, Dorota Zarębska-Michaluk
, Sona Frankova
, Ivica Grgurevic
, Bela Hunyady
, Peter Jarcuska
, Limas Kupčinskas
, Michael Makara
, Marieta Simonova
, Jan Sperl
, Ieva Tolmane
, Adriana Vince

Medical University of Białystok
Jan Kochanowski University in Kielce
University of Pecs
Louis Pasteur University Hospital
Riga East University Hospital

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

According to the recent data presented by Central-European HCV experts, the estimated prevalence of HCV is between 0.2% and 1.7% in certain countries in this region. There are no financial limitations to access to treatment in most countries. Patients in these countries have access to at least one pangenotypic regimen. The most common barriers to the elimination of HCV in Central Europe are a lack of established national screening programmes and limited political commitment to the elimination of HCV. Covid-19 has significantly affected the number of patients who have been diagnosed and treated, thus, delaying the potential elimination of HCV. These data suggest that the elimination of HCV elimination projected by WHO before 2030 will not be possible in the Central Europe.

Original language	English
Pages (from-to)	56-60
Journal	Liver International
Volume	41
Issue number	S1
DOIs	https://doi.org/10.1111/liv.14834
Publication status	Published - Jun 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

epidemiology
hepatitis C virus
liver
therapy

OECD Field of Science

3. Medical and Health Sciences

Access to Document

10.1111/liv.14834

Cite this

@article{6a732a46c8d741a5a101c42b006f0861,

title = "Is elimination of HCV in 2030 realistic in Central Europe",

abstract = "According to the recent data presented by Central-European HCV experts, the estimated prevalence of HCV is between 0.2\% and 1.7\% in certain countries in this region. There are no financial limitations to access to treatment in most countries. Patients in these countries have access to at least one pangenotypic regimen. The most common barriers to the elimination of HCV in Central Europe are a lack of established national screening programmes and limited political commitment to the elimination of HCV. Covid-19 has significantly affected the number of patients who have been diagnosed and treated, thus, delaying the potential elimination of HCV. These data suggest that the elimination of HCV elimination projected by WHO before 2030 will not be possible in the Central Europe.",

keywords = "epidemiology, hepatitis C virus, liver, therapy",

author = "Robert Flisiak and Dorota Zar{\c e}bska-Michaluk and Sona Frankova and Ivica Grgurevic and Bela Hunyady and Peter Jarcuska and Limas Kup{\v c}inskas and Michael Makara and Marieta Simonova and Jan Sperl and Ieva Tolmane and Adriana Vince",

note = "Publisher Copyright: {\textcopyright} 2021 John Wiley \& Sons A/S. Published by John Wiley \& Sons Ltd",

year = "2021",

month = jun,

doi = "10.1111/liv.14834",

language = "English",

volume = "41",

pages = "56--60",

journal = "Liver International",

issn = "1478-3223",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "S1",

}

TY - JOUR

T1 - Is elimination of HCV in 2030 realistic in Central Europe

AU - Flisiak, Robert

AU - Zarębska-Michaluk, Dorota

AU - Frankova, Sona

AU - Grgurevic, Ivica

AU - Hunyady, Bela

AU - Jarcuska, Peter

AU - Kupčinskas, Limas

AU - Makara, Michael

AU - Simonova, Marieta

AU - Sperl, Jan

AU - Tolmane, Ieva

AU - Vince, Adriana

PY - 2021/6

Y1 - 2021/6

N2 - According to the recent data presented by Central-European HCV experts, the estimated prevalence of HCV is between 0.2% and 1.7% in certain countries in this region. There are no financial limitations to access to treatment in most countries. Patients in these countries have access to at least one pangenotypic regimen. The most common barriers to the elimination of HCV in Central Europe are a lack of established national screening programmes and limited political commitment to the elimination of HCV. Covid-19 has significantly affected the number of patients who have been diagnosed and treated, thus, delaying the potential elimination of HCV. These data suggest that the elimination of HCV elimination projected by WHO before 2030 will not be possible in the Central Europe.

AB - According to the recent data presented by Central-European HCV experts, the estimated prevalence of HCV is between 0.2% and 1.7% in certain countries in this region. There are no financial limitations to access to treatment in most countries. Patients in these countries have access to at least one pangenotypic regimen. The most common barriers to the elimination of HCV in Central Europe are a lack of established national screening programmes and limited political commitment to the elimination of HCV. Covid-19 has significantly affected the number of patients who have been diagnosed and treated, thus, delaying the potential elimination of HCV. These data suggest that the elimination of HCV elimination projected by WHO before 2030 will not be possible in the Central Europe.

KW - epidemiology

KW - hepatitis C virus

KW - liver

KW - therapy

UR - https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14834

UR - https://www.scopus.com/pages/publications/85108239114

U2 - 10.1111/liv.14834

DO - 10.1111/liv.14834

M3 - Article

C2 - 34155796

SN - 1478-3223

VL - 41

SP - 56

EP - 60

JO - Liver International

JF - Liver International

IS - S1

ER -

Is elimination of HCV in 2030 realistic in Central Europe

Abstract

UN SDGs

Keywords

OECD Field of Science

Access to Document

Other files and links

Fingerprint

Cite this